[Therapeutic role of coagulation in small cell lung cancers].
Biological data and several experimental works have shown evidence of the important relationship that exists between the development of the neoplastic process and phenomena linked to blood coagulation. This relationship would appear particularly important in small cell bronchopulmonary cancer. Several therapeutic trials are attached to confirming in vivo the hopes furnished by the series on the mechanism of thrombosis in associating chemotherapy with coagulation therapy. If Aspirin used in a dose for anti-platelet aggregation is revealed as being insufficient then anti-Vitamin K and standard Heparin have brought an undeniable benefit to the level of response and survival in phase three randomised trials. Urokinase also brings a promising improvement in an open phase two trial but has to be confirmed.
LeBeau
B
B
Service de pneumologie, Hôpital Saint-Antoine, Paris.
D000925:Anticoagulants / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D018288:Carcinoma, Small Cell / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors
Rôle des thérapeutiques de la coagulation dans les cancers bronchiques à petites cellules.